Background: Ventriculitis is a severe central nervous system infection, often secondary to intraventricular device use or neurosurgical procedures, with high morbidity and mortality. Diagnostic criteria remain debated and treatment strategies lack standardization. Methods: We conducted a retrospective cohort study from 2014 to 2022 to describe the clinical characteristics, microbiological profile, treatment strategies, and outcomes of ventriculitis at a tertiary care center. Additionally, we compared outcomes before and after the implementation of an updated intraventricular device management protocol. Results: A total of 403 positive CSF cultures were identified during the study period. Among these, 87 fulfilled clinical and microbiological criteria for ventriculitis. Healthcare-associated cases predominated (73, 83.9%), with neurosurgical interventions (72, 82.8%) and external ventricular drain use (54, 62.1%) as the most prevalent risk factors. The most common pathogens were coagulase-negative Staphylococci (42, 48.3%), particularly Staphylococcus epidermidis (33, 37.9%). Fever (56, 64.4%) and altered consciousness (40, 45.9%) were the most frequent symptoms. Attributable mortality reached 33.3% (29/87), increasing to 39.1% (34/87) within one-year post-episode. The introduction of the updated protocol may have contributed to a reduction in mortality between the study periods [RR 0.45 (0.32–0.78) p=0.003]. Among discharged patients, 67.3% (37/55) experienced neurological sequelae. Predictors of higher mortality included CSF protein ≥1 mg/mL at diagnosis and a Glasgow Coma Scale score ≤8 during the clinical course. Conclusions: Ventriculitis remains a complex and life-threatening condition with considerable diagnostic and management challenges. Our findings suggest that standardized intraventricular device care protocols may contribute to improved outcomes, although further evaluation is needed.